ALK3

ALK3, also known as BMPR1A, is a type I bone morphogenetic protein (BMP) receptor that mediates signaling within the TGF-β/BMP superfamily and functions through receptor complexes composed of type I and type II receptors^[1][2]. Upon BMP ligand binding, activated receptor complexes phosphorylate BMP-responsive SMAD1/5/8, thereby transmitting canonical signaling and coordinating additional non-canonical pathways involved in development and tissue homeostasis^[1][2]. Mechanistically, ALK3-dependent BMP signaling regulates cell fate determination, skeletal development, and postnatal bone formation, and global loss of ALK3 results in embryonic lethality, highlighting its essential biological role^[2][1]. In disease and experimental settings, dysregulated BMP signaling is linked to multiple developmental and skeletal abnormalities, while genetic mouse models with altered BMP pathway activity have provided valuable systems for studying disease mechanisms and therapeutic intervention^[1][1]. ALK3 also contributes to vascular biology, where BMP signaling through ALK3/BMPR1A and SMAD1/5 has been shown to control venous identity in vivo^[2]. Compared with related BMP type I receptors, ALK3 shares some functional similarities with ALK2 but displays distinct developmental requirements and broader roles in tissue morphogenesis, whereas it also exhibits substantial sequence similarity to ALK6^[2]. For experimental applications, small-molecule BMP type I receptor inhibitors, including compounds that inhibit ALK3 kinase activity, are widely used to modulate BMP signaling and investigate BMP-dependent biological processes and disease models^[2][5].